Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2523-8973
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis ; day:25 ; month:1 ; year:2021 ; pages:1-17
SN comprehensive clinical medicine ; (25.1.2021), 1-17
- Urheber
-
Hock, Emma Stefania
Martyn-St James, Marrissa
Wailoo, Allan
Scott, David L.
Stevenson, Matt
Rawdin, Andrew
Simpson, Emma L.
Dracup, Naila
Young, Adam
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s42399-021-00727-4
- URN
-
urn:nbn:de:101:1-2021031718185832822926
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hock, Emma Stefania
- Martyn-St James, Marrissa
- Wailoo, Allan
- Scott, David L.
- Stevenson, Matt
- Rawdin, Andrew
- Simpson, Emma L.
- Dracup, Naila
- Young, Adam
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Cost-effectiveness analysis of biological agents for rheumatoid arthritis in Germany
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
The potential role of fatigue in difficult-to-treat rheumatoid arthritis
Total hip arthroplasty to treat acetabular protrusions secondary to rheumatoid arthritis
Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Cost-effectiveness analysis of biological agents for rheumatoid arthritis in Germany
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
The potential role of fatigue in difficult-to-treat rheumatoid arthritis
Total hip arthroplasty to treat acetabular protrusions secondary to rheumatoid arthritis
Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Cost-effectiveness analysis of biological agents for rheumatoid arthritis in Germany
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
The potential role of fatigue in difficult-to-treat rheumatoid arthritis
Total hip arthroplasty to treat acetabular protrusions secondary to rheumatoid arthritis
Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran